Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Associate Professor of Clinical Medicine
University of California San Diego
San Diego, CA

Topics of Professional Interest:
  • HCV infection
  • Opportunistic infections in AIDS
  • Immune restoration after HAART
  • Immune recovery syndromes
  • HCV infection in HIV-infected patients
  • CMV retinitis
Current Professional Summary:

Dr Torriani is an Attending Physician in the Department of Medicine and the Division of Infectious Diseases at the University of California San Diego, specializing in infectious diseases, HIV, and HCV. In addition, Dr Torriani teaches in the UCSD Patient Oriented Research Course on Clinical Trials Design and Implementation.
         

Committees and Organizations:
  • Member, ACTG Cardiovascular Focus Group (1998–)
  • Member, UCSD Risk Management Committee (1998–)
  • Member, UCSD Recruitment and Admission Committee (1998–)
  • Member, UCSD Patient Care Committee (2000–)
  • Member, ACTG Immunology Research Agenda Committee (2000–)
  • Member, ACTG Liver Diseases Focus Group (2001–)
Education:
  • Liceo Cantonale di Lugano, Switzerland, BS, Literature/Latin (1977)
  • University of Lausanne Medical School, Lausanne, Switzerland, MD (1985)
  • University Hospital of Lausanne; Residency in Internal Medicine (1987–1989) Chief Resident in Internal Medicine (1989–1992)
  • University of California San Diego, Fellowship in Infectious Diseases (1992–1995)
Selected Publications:
  1. Torriani FJ, McCutchan JA, Bozzette SA, Grafe MR, Havlir DV. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis. 1994;170:1601-1605.
  2. Havlir D, Torriani FJ, Dube M. Uveitis associated with rifabutin prophylaxis. Ann Intern Med. 1994;121:510-512.
  3. Torriani FJ, Behling C, McCutchan JA, Haubrich RH, Havlir DV. Disseminated Mycobacterium avium complex (MAC): correlation between blood and tissue burden. J Infect Dis. 1996;173:942-949.
  4. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC, Witt MD, Bozzette SA, McCutchan JA, Nightingale SD, Sepkowitz KA, MacGregor RR, Cheeseman SH, Torriani FJ, Zelasky MT, Williams DJ, Hopkins SJ, Kuma PN, the California Collaborative Treatment Group (CCTG). Prophylaxis of disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin or both drugs. N Engl J Med. 1996;335:392-398.
  5. Macdonald JC, Torriani FJ, Morse LS, Karavellas M, Reed JB, Freeman WR. Lack of progression and re-activation of cytomegalovirus retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4+ T cells in response to highly active antiretroviral therapy. J Infect Dis. 1998;177:1182-1187.
  6. Dubé MP, Torriani FJ, See D, Havlir DV, Kemper CA, Leedom JM, Tilles JG, McCutchan JA, Sattler FR. Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. Clin Infect Dis. 1999;28:136-138.
  7. Torriani FJ, Freeman WR, Macdonald JC, Karavellas MP, Durand DM, Jeffrey DD, Meylan PRA, Schrier RD. CMV retinitis recurs after stopping CMV treatment in virologic and immunologic failures of potent antiretroviral therapy. AIDS. 2000;14:173-180.
  8. Torriani FJ, Soriano V. Chronic hepatitis C in HIV-infected individuals. AIDS Reviews. 2000;2:169-178.
  9. Dubé MP, Sprecher D, Henry WK, Aberg JA, Torriani FJ, Hodis HN, Schouten J, Levin J, Myers G, Zackin R, Nevin T, Currier JS, for the Adult ACTG Cardiovascular Disease Focus Group. Preliminary guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretriviral therapy: recommendations of the Adult ACTG Cardiovascular Disease Focus Group. Clin Infect Dis. 2000;31:1216-1224.
  10. Havlir DV, Torriani FJ, Schrier RD, Hwang JY, Lederman MM, Chervenak KA, Boom WH. Serum interleukin-6 (IL-6), IL-1-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J Clin Microbiol. 2001;39:298-303.
  11. Koletar SL, Heald AE, Finkelstein D, Hafner R, Currier JS, McCutchan JA, Vallee M, Torriani FJ, Powderly WG, Fass RJ, Murphy RL, for the ACTG 888 Study Team. A prospective study of discontinuing primary and secondary Pneumocystis carinii prophylaxis after CD4+ counts increase to > 200 cells/mm. AIDS. 2001. In press.